{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:02:16Z","timestamp":1790758936573,"version":"4.1.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases such as coronary atherosclerosis, and ApoB may be one of the most accurate markers for assessing atherosclerotic cardiovascular disease (ASCVD) risk. This review discusses the limitations of conventional lipid measures, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), and systematically examines the advantages of ApoB as an alternative marker for cardiovascular risk assessment, as well as its independent predictive value. In addition, this review discusses the clinical utility, potential advantages, and challenges associated with ApoB, as well as the effects of currently available lipid-lowering therapies on ApoB and recent advances in the development of ApoB-targeted therapies, with the aim of informing more precise strategies for the prevention and treatment of cardiovascular disease.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1857230","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:25:32Z","timestamp":1790756732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers"],"prefix":"10.3389","volume":"13","author":[{"given":"Lingling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Yu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxin","family":"Sun","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqing","family":"Hu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidong","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Geriatrics Dept, Zhongshan Hospital of Traditional Chinese Medicine","place":["Zhongshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","article-title":"Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors","volume":"121","author":"Joseph","year":"2017","journal-title":"Circulation Rresearch"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics\u20132013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/2047487315612733","article-title":"The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: the jackson heart study","volume":"23","author":"May","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.3390\/nu17132244","article-title":"Polygenic risk, modifiable lifestyle behaviors, and metabolic factors: associations with HDL-C, triglyceride levels, and cardiovascular risk","volume":"17","author":"Chermon","year":"2025","journal-title":"Nutrients"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet (London, England)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","article-title":"Excess apolipoprotein B and cardiovascular risk in women and men","volume":"83","author":"Johannesen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1194\/jlr.R082271","article-title":"Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding","volume":"59","author":"Sniderman","year":"2018","journal-title":"J Lipid Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.1038\/s41586-018-0313-x","article-title":"Publisher correction: oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"561","author":"Que","year":"2018","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1161\/CIRCULATIONAHA.111.051599","article-title":"Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses","volume":"124","author":"Ketelhuth","year":"2011","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1001\/archinternmed.2010.384","article-title":"Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish","volume":"170","author":"Shen","year":"2010","journal-title":"Arch Intern Med"},{"key":"B16","first-page":"11","article-title":"Common and rare gene variants affecting plasma LDL cholesterol","volume":"29","author":"Burnett","year":"2008","journal-title":"The Clinical Biochemist Reviews"},{"key":"B17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41586-024-08223-0","article-title":"Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor","volume":"638","author":"Reimund","year":"2025","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41586-024-08467-w","article-title":"The structure of apolipoprotein B100 from human low-density lipoprotein","volume":"638","author":"Berndsen","year":"2025","journal-title":"Nature"},{"key":"B19","article-title":"Introduction to lipids and lipoproteins. [Updated 2024 Jan 14]","volume-title":"Endotext [Internet]","author":"Feingold","year":"2000"},{"key":"B20","first-page":"117","article-title":"Apolipoprotein B-48: a unique marker of chylomicron metabolism","volume-title":"Advances in Clinical Chemistry","author":"Nakajima","year":"2014"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1073\/pnas.94.9.4647","article-title":"Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages","volume":"94","author":"Fazio","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5551\/jat.64920","article-title":"Proteomic analysis of human chylomicron remnants isolated by apolipoprotein B-48 immunoprecipitation","volume":"32","author":"Masuda","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0009-3084(94)90128-7","article-title":"Primary structure of apoB-100","author":"Yang","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"B24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1039\/B700706J","article-title":"The physiological and molecular regulation of lipoprotein assembly and secretion","volume":"3","author":"Blasiole","year":"2007","journal-title":"Mol BioSyst"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"110547","DOI":"10.1016\/j.mce.2019.110547","article-title":"Endoplasmic reticulum quality control in lipoprotein metabolism","volume":"498","author":"Koerner","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/srep00139","article-title":"A phospholipidomic analysis of all defined human plasma lipoproteins","volume":"1","author":"Dashti","year":"2011","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1172\/JCI113273","article-title":"Structural relationship of human apolipoprotein B48 to apolipoprotein B100","volume":"80","author":"Innerarity","year":"1987","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1161\/01.ATV.19.12.2966","article-title":"Human apolipoprotein (apo) B-48 and ApoB-100 kinetics with stable isotopes","volume":"19","author":"Welty","year":"1999","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1365-2362.1999.00431.x","article-title":"Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state","volume":"29","author":"Smith","year":"1999","journal-title":"Eur J Clin Investig"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.5551\/jat.10470","article-title":"Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia","volume":"18","author":"Masuda","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1038\/s41598-019-40385-0","article-title":"Fasting apolipoprotein B48 is associated with large artery atherosclerotic stroke: a case-control study","volume":"9","author":"Tian","year":"2019","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1161\/CIR.0000000000001172","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"148","year":"2023","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12265-011-9264-4","article-title":"Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research","volume":"4","author":"Chen","year":"2011","journal-title":"J Cardiovasc Transl Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0022-2275(20)38265-1","article-title":"Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100","volume":"30","author":"Albers","year":"1989","journal-title":"J Lipid Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.3390\/jcm12175737","article-title":"Use of apolipoprotein B in the era of precision medicine: time for a paradigm change?","volume":"12","author":"Cole","year":"2023","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1373\/clinchem.2010.154773","article-title":"Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population","volume":"57","author":"van Deventer","year":"2011","journal-title":"Clin Chem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0140-6736(79)91375-8","article-title":"Are apolipoproteins better discriminators than lipids for atherosclerosis?","volume":"1","author":"Avogaro","year":"1979","journal-title":"Lancet (London, England)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2018.11.001","article-title":"Apob in clinical care: pro and con","volume":"282","author":"Sniderman","year":"2019","journal-title":"Atherosclerosis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","article-title":"Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study","volume":"67","author":"Wilkins","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1097\/MD.0000000000003644","article-title":"Prediction of future development of cardiovascular disease with an equation to estimate apolipoprotein B: a community-based cohort study","volume":"95","author":"Hwang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.clinthera.2022.06.010","article-title":"Apolipoprotein B displays superior predictive value than other lipids for long-term prognosis in coronary atherosclerosis patients and particular subpopulations: a retrospective study","volume":"44","author":"Zhang","year":"2022","journal-title":"Clin Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.amjcard.2023.05.052","article-title":"Apolipoprotein particle and cardiovascular risk prediction (from a prospective cohort study)","volume":"201","author":"Su","year":"2023","journal-title":"Am J Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the national lipid association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"822626","DOI":"10.3389\/fcvm.2022.822626","article-title":"Paradoxical association between baseline apolipoprotein B and prognosis in coronary artery disease: a 36,460 Chinese cohort study","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1161\/01.ATV.0000255580.73689.8e","article-title":"Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen city heart study","volume":"27","author":"Benn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/ije\/dyaa216","article-title":"High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease","volume":"50","author":"Zuber","year":"2021","journal-title":"Int J Epidemiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12933-024-02140-2","article-title":"Revisiting an old relationship: the causal associations of the ApoB\/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a Mendelian randomization analysis","volume":"23","author":"Fu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"22","author":"Bor\u00e9n","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1201\/9780203748831-2","article-title":"Cellular interactions of lipoproteins with the vascular endothelium: endocytosis and transcytosis","volume":"5","author":"Simionescu","year":"1991","journal-title":"Targeted Diagn Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1083\/jcb.96.6.1677","article-title":"Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ","volume":"96","author":"Vasile","year":"1983","journal-title":"J Cell Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The response-to-retention hypothesis of early atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-019-0169-2","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"B\u00e4ck","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/joim.12367","article-title":"Regulation of atherosclerotic plaque inflammation","volume":"278","author":"B\u00e4ck","year":"2015","journal-title":"J Intern Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1196033","DOI":"10.3389\/fimmu.2023.1196033","article-title":"Monocyte-endothelial cell interactions in vascular and tissue remodeling","volume":"14","author":"Medrano-Bosch","year":"2023","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.3390\/ijms24119568","article-title":"The role of macrophages in atherosclerosis: pathophysiologic mechanisms and treatment considerations","volume":"24","author":"Theofilis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"118552","DOI":"10.1016\/j.atherosclerosis.2024.118552","article-title":"Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: a critical review","volume":"397","author":"Kumarapperuma","year":"2024","journal-title":"Atherosclerosis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1194\/jlr.R800099-JLR200","article-title":"Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis","volume":"50","author":"Libby","year":"2009","journal-title":"J Lipid Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e213715","DOI":"10.1212\/WNL.0000000000213715","article-title":"Association of blood lipoprotein levels with incident Alzheimer disease in community-dwelling individuals: the framingham heart study","volume":"104","author":"Charisis","year":"2025","journal-title":"Neurology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/archneur.64.1.103","article-title":"Twenty-six-year change in total cholesterol levels and incident dementia: the honolulu-Asia aging study","volume":"64","author":"Stewart","year":"2007","journal-title":"Arch Neurol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.eclinm.2022.101695","article-title":"Serum lipid traits and the risk of dementia: a cohort study of 254,575 women and 214,891 men in the UK biobank","volume":"54","author":"Gong","year":"2022","journal-title":"eClinicalMed"},{"key":"B73","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s42003-024-05887-2","article-title":"Mendelian randomization reveals apolipoprotein B shortens healthspan and possibly increases risk for Alzheimer\u2019s disease","volume":"7","author":"Martin","year":"2024","journal-title":"Commun Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.jlr.2024.100667","article-title":"Apolipoprotein B gene expression and regulation in relation to Alzheimer\u2019s disease pathophysiology","volume":"65","author":"Aumont-Rodrigue","year":"2024","journal-title":"J Lipid Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e40191","DOI":"10.1016\/j.heliyon.2024.e40191","article-title":"Association analyses of nutritional markers with Parkinson\u2019s disease and Alzheimer\u2019s disease","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3233\/JPD-212670","article-title":"Blood cholesterol decreases as Parkinson\u2019s disease develops and progresses","volume":"11","author":"Wang","year":"2021","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2147\/OPTH.S527436","article-title":"Serum apolipoprotein B and B\/A1 ratio as early negative biomarkers for OCT- and OCTA-detected retinal changes in diabetic macular edema","volume":"19","author":"Soedarman","year":"2025","journal-title":"Clinical Ophthalmology (Auckland, NZ)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e85656","DOI":"10.7759\/cureus.85656","article-title":"Apolipoprotein B and glycemic indices in normoglycemic adults: analysis of the national health and nutrition examination survey, 2007\u20132016","volume":"17","author":"Agoons","year":"2025","journal-title":"Cureus"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00592-021-01775-x","article-title":"Association of serum apolipoprotein B with retinal neurovascular structural alterations in patients with type 2 diabetes: an optical coherence tomography angiography study","volume":"58","author":"Shi","year":"2021","journal-title":"Acta Diabetol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/ckj\/sfz186","article-title":"Apolipoprotein B is a risk factor for end-stage renal disease","volume":"14","author":"Kwon","year":"2021","journal-title":"Clin Kidney J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1083614","DOI":"10.3389\/fendo.2023.1083614","article-title":"The association of apolipoprotein B with chronic kidney disease in the Chinese population","volume":"14","author":"Xu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.7150\/jca.35659","article-title":"Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients","volume":"11","author":"Yang","year":"2020","journal-title":"J Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.1038\/s41598-025-97625-9","article-title":"Association of ApoB\/apoA1 ratio with stenosis of intracranial and extracranial arteries in patients with ischaemic stroke","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1210\/jc.2007-0221","article-title":"Polymorphisms in apolipoprotein B and risk of ischemic stroke","volume":"92","author":"Benn","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.3390\/nu15214670","article-title":"High ApoB\/ApoA-I ratio predicts post-stroke cognitive impairment in acute ischemic stroke patients with large artery atherosclerosis","volume":"15","author":"Lee","year":"2023","journal-title":"Nutrients"},{"key":"B86","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12883-016-0766-1","article-title":"Ratio of apoB\/LDL: a potential clinical index for vascular cognitive impairment","volume":"16","author":"Qian","year":"2016","journal-title":"BMC Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1136\/annrheumdis-2018-213444","article-title":"Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis","volume":"77","author":"Lee","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2020.05.001","article-title":"The clinical utility of apoB versus LDL-C\/non-HDL-C","volume":"508","author":"Kohli-Lynch","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e030405","DOI":"10.1161\/JAHA.123.030405","article-title":"Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol","volume":"12","author":"Contois","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B92","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"key":"B93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"key":"B94","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"key":"B95","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e0212539","DOI":"10.1371\/journal.pone.0212539","article-title":"Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease","volume":"14","author":"Ohwada","year":"2019","journal-title":"PLoS One"},{"key":"B97","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jacl.2019.05.009","article-title":"Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines","volume":"13","author":"Grundy","year":"2019","journal-title":"J Clin Lipidol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B99","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2796.2010.02277.x","article-title":"Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk","volume":"268","author":"Holewijn","year":"2010","journal-title":"J Intern Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12944-019-1144-y","article-title":"Comparison of apolipoprotein B\/A1 ratio, framingham risk score and TC\/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention","volume":"18","author":"Tian","year":"2019","journal-title":"Lipids Health Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","article-title":"Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events","volume":"129","author":"Mora","year":"2014","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e000759","DOI":"10.1161\/JAHA.113.000759","article-title":"Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials","volume":"3","author":"Thanassoulis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1194\/jlr.P800061-JLR200","article-title":"Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia","volume":"50","author":"Tremblay","year":"2009","journal-title":"J Lipid Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/01.ATV.0000216750.09611.ec","article-title":"Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia","volume":"26","author":"Tremblay","year":"2006","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e014129","DOI":"10.1161\/JAHA.119.014129","article-title":"Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies","volume":"9","author":"Toth","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"B112","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"Jama"},{"key":"B115","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet (London, England)"},{"key":"B116","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamacardio.2024.1310","article-title":"Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels","volume":"9","author":"Sayed","year":"2024","journal-title":"JAMA Cardiology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacl.2017.12.013","article-title":"A comparison of three apolipoprotein B methods and their associations with incident coronary heart disease risk over a 12-year follow-up period: the multi-ethnic study of atherosclerosis","volume":"12","author":"Cao","year":"2018","journal-title":"J Clin Lipidol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00431-023-05350-0","article-title":"Tracking of apolipoprotein B levels measured in childhood and adolescence: systematic review and meta-analysis","volume":"183","author":"Stanesby","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e003665","DOI":"10.1161\/JAHA.116.003665","article-title":"Age and cardiovascular risk attributable to apolipoprotein B, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol","volume":"5","author":"Sniderman","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1857230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:25:33Z","timestamp":1790756733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1857230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":121,"alternative-id":["10.3389\/fcvm.2026.1857230"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1857230","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1857230"}}